VRTXVertex Pharmaceuticals IncorporatedRunning, no new patients
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Myasthenia Gravis, Generalized
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 34 (final count)
- Started
- May 13, 2026
- Main results expected
- Mar 2, 2029
- Fully finished
- Mar 2, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percent change in Total Immunoglobulin G (IgG)
Measured over: Baseline and At Week 12
Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From Baseline Up to Week 116
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07501702 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC